Onderneming Flex Pharma Inc Nasdaq
Aandelen
US33938A1051
Biotechnologie & Medisch Onderzoek
Vakgebied
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
David Arthur
CEO | Chief Executive Officer | 61 | 19-07-19 |
Mark Rosenblum
DFI | Director of Finance/CFO | 70 | 10-09-19 |
Bruce McCreedy
BRD | Director/Board Member | 64 | 19-07-19 |
Nadeem Q. Mirza
PRN | Corporate Officer/Principal | - | 23-07-20 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Arnold Hanish
BRD | Director/Board Member | 76 | 19-07-19 |
Paul Lammers
BRD | Director/Board Member | 66 | 19-07-19 |
Jonathan Lieber
BRD | Director/Board Member | 54 | 19-06-20 |
William McVicar
CHM | Chairman | 66 | 19-07-19 |
Bruce McCreedy
BRD | Director/Board Member | 64 | 19-07-19 |
Tess Burleson
BRD | Director/Board Member | 57 | 19-07-19 |
David Arthur
CEO | Chief Executive Officer | 61 | 19-07-19 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 597 054 | 560 776 ( 93,92 %) | 0 | 93,92 % |
Bedrijfsgegevens
Salarius Pharmaceuticals, Inc.
2450 Holcombe Boulevard Suite X
77021, Houston
+
http://salariuspharma.comSector
Vaira. 1 jan. | Kapi. | |
---|---|---|
+25,83% | 46,56 mld. | |
+45,38% | 41,67 mld. | |
+0,69% | 41,16 mld. | |
+30,52% | 32,4 mld. | |
+22,30% | 28,18 mld. | |
-6,35% | 28,1 mld. | |
+49,25% | 14,52 mld. | |
+49,18% | 13,74 mld. | |
+3,45% | 12,17 mld. |